The U.S. FDA-approved Darunavir to treat people with HIV infection on June 23, 2006.

Darunavir has been developed to treat Human Immunodeficiency Virus (HIV-1). Darunavir tablet is indicated as a complete regimen for treating adults and children older than three years of age infected with HIV 1.

Take the Darunavir tablet as advised by your physician. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

The common side effects that are likely to occur while you are on the treatment with Darunavir are diarrhea, nausea, rash, headache, stomach pain, vomiting, changes in taste, dizziness, weakness, tiredness, loss of appetite, and tingling sensation. If you experience allergic reactions after taking this tablet, immediately report it to your doctor.

Serious side effects while taking Darunavir are liver problems, skin rash and itching, diabetes, and unusual bleeding.

Do not take this medication if you have experienced hypersensitivity reactions to Darunavir or its ingredients. Report to your doctor if you have been diagnosed with hemophilia, bone disease (osteonecrosis), diabetes hepatitis B, hepatitis C, or liver condition. Contact your physician immediately if you notice any musculoskeletal problems (joint aches, stiffness, and pains, particularly in the hip, knee, and shoulder, and difficulty in movement.

Adults of childbearing potential should consider using an effective contraceptive to prevent unwanted pregnancy. Before starting this treatment, tell your doctor if you are pregnant or planning to have a baby. Breastfeeding is not recommended due to the potential transmission of HIV from the mother to the baby.

Darunavir can make you feel dizzy and tired. Hence, you should avoid driving or handling machines during this treatment. Store Darunavir, Ritonavir Tablets at room temperature, away from the reach of children. Store the tablets in the original container and protect them from heat.

1. Dr. Reddy's Laboratories (UK) Ltd, Electronic Medicines Compendium (EMC), [Revised on Apr 2021] [Accessed on15th May 2023], https://www.medicines.org.uk/emc/files/pil.9979.pdf
2. Cipla Ltd., [Revised on 14th May 2020] [Accessed on 15th May 2023], https://www.ciplamed.com/print-product-pdf/35307
3. Janssen Pharmaceutical Companies, [Revised on Feb 2021] [Accessed on 15th May 2023], https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/PREZISTA-pi.pdf
4. KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872.
5. Sharon Safrin, Antiviral Agents, Lange's Basic & Clinical Pharmacology, 14th Edition, 2018, 863-894.

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.